3D-PharmXchange congratulates MimeCure on raising €3 million to accelerate the development of its therapy for chronic lung diseases, including Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD). The investment round is led by Addington Investment Group, with Apsara Investments as co-investor. The funds will support MimeCure in completing the preclinical phase and preparing continue reading…